Scientific Opinion on the substantiation of a health claim related to a combination of bifidobacteria (Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum) and decreasing potentially pathogenic intestinal microorganisms pursuant to Article 14 of Regulation (EC) No 1924/2006

Tabs

Article
Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, bifidobacteriapotentially pathogenic intestinal microorganisms, health claims.
First published in the EFSA Journal
21 December 2009
Adopted
4 December 2009
Type
Opinion of the Scientific Committee/Scientific Panel
Abstract

Following an application from Töpfer GmbH submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to a combination of bifidobacteria (Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum) and decreasing potentially pathogenic intestinal microorganisms. The scope of the application was proposed to fall under a health claim referring to children’s development and health. The food constituent that is the subject of the proposed claim, a combination of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, has not been sufficiently characterised. The claimed effect is “establishment of a natural, beneficial bifidobacterial dominance in the large intestine, which can lead to a suppression of harmful bacteria and thereby to a better health status”. The target population is infants and children aged between 0 to 36 months. The Panel considers that decreasing potentially pathogenic intestinal microorganisms might be beneficial to human health. The applicant identified a total of 34 publications considered as being pertinent to the health claim. In weighing the evidence, the Panel notes that the strains that are the subject of the health claim have not been sufficiently characterised and that from the evidence provided it cannot be established that the strains used in the studies are the same strains that are the subject of the claim.

 

Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Panel on Dietetic Products, Nutrition and Allergies
Contact
nda [at] efsa.europa.eu
doi
10.2903/j.efsa.2009.1420
EFSA Journal 2009; 7(12):1420 [8 pp.].
Question Number
On request from
Töpfer GmbH
Print on demand
Number of Pages
8